Get the Stockscreener App
8.25
12.03%
-1.10
Personalis Inc stock is traded at $8.25, with a volume of 911.16K.
It is down -12.03% in the last 24 hours and down -16.24% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$9.35
Open:
$8.94
24h Volume:
911.16K
Relative Volume:
0.62
Market Cap:
$732.63M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.6667
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
+3.33%
1M Performance:
-16.24%
6M Performance:
+19.90%
1Y Performance:
+46.88%
1-Day Range:
$8.11
$9.0236
1-Week Range:
$7.7201
$9.74
52-Week Range:
$2.8262
$11.40
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.2499 | 830.32M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
614.20 | 231.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.33 | 166.39B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
710.18 | 57.06B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
146.96 | 41.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
243.09 | 41.60B | 15.90B | 1.28B | 2.21B | 7.2842 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace
PSNL Achieves Key Medicare Coverage Milestone for Breast Cancer - GuruFocus
Personalis (PSNL) Achieves Remarkable Growth in Clinical Volumes - GuruFocus
Institutional Investors Are Personalis, Inc.'s (NASDAQ:PSNL) Biggest Bettors and Were Rewarded After Last Week's US$105m Market Cap Gain - 富途牛牛
Personalis (NASDAQ:PSNL) delivers shareholders splendid 54% CAGR over 3 years, surging 15% in the last week alone - simplywall.st
Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Will Personalis Inc stock remain a Wall Street favoriteJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - moha.gov.vn
Quant Funds Rotate Into Pavna Industries Limited StockTechnical Analysis Insights & Stay Invested. Stay Smart. - earlytimes.in
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) - Insider Monkey
Personalis Outpaces The Market With Cancer Test Breakthroughs - Finimize
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Personalis Inc. (04X) stock split increase liquidityRate Cut & Entry and Exit Point Strategies - Улправда
How Personalis Inc. stock reacts to bond yieldsWeekly Trading Summary & Safe Entry Point Alerts - ulpravda.ru
Is Personalis Inc. stock attractive for hedge funds2025 Bull vs Bear & Community Consensus Trade Signals - Улправда
Personalis (NASDAQ:PSNL) Sees Strong Trading VolumeHere's Why - MarketBeat
Will Personalis Inc. stock remain a Wall Street favoriteJuly 2025 Trends & Free High Return Stock Watch Alerts - Bölüm Sonu Canavarı
Nasdaq Moves: How Personalis Inc. stock reacts to bond yieldsWeekly Stock Recap & Reliable Price Action Trade Plans - ulpravda.ru
Aug Opening: How risky is Personalis Inc. stock nowTrade Exit Summary & Daily Price Action Insights - Улправда
Revenue Check: Will Personalis Inc. (04X) stock split increase liquidityJuly 2025 Price Swings & Daily Price Action Insights - Улправда
How risky is Personalis Inc. stock nowJuly 2025 Earnings & Safe Investment Capital Preservation Plans - Улправда
Personalis study shows cancer blood test predicts immunotherapy outcomes By Investing.com - Investing.com Nigeria
Personalis study shows cancer blood test predicts immunotherapy outcomes - Investing.com
Personalis announces new publication applying ultrasensitive ctDNA testing - marketscreener.com
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors - Business Wire
Personalis (NASDAQ:PSNL) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer - Business Wire
Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds - Yahoo Finance
Personalis, Inc. $PSNL Shares Purchased by Blue Water Life Science Advisors LP - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 38% But Its P/S Still Looks Reasonable - 富途牛牛
Personalis (NASDAQ:PSNL) Stock Price Down 4.8%What's Next? - MarketBeat
Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen - MarketBeat
Is Personalis Inc. (04X) stock undervalued by metricsEarnings Miss & Short-Term High Return Strategies - Newser
Geode Capital Management LLC Buys 851,422 Shares of Personalis, Inc. $PSNL - MarketBeat
Will Personalis Inc. (04X) stock maintain strong growthWeekly Volume Report & Growth Focused Investment Plans - Newser
Will Personalis Inc. (04X) stock beat Nasdaq index returns2025 Short Interest & Real-Time Volume Spike Alerts - Newser
Will Personalis Inc. (04X) stock outperform Dow JonesMarket Risk Summary & Fast Moving Market Watchlists - Newser
How Personalis Inc. stock performs during Fed tightening cycles2025 Growth vs Value & Weekly Chart Analysis and Trade Guides - Newser
Will Personalis Inc. stock reach Wall Street targetsInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Personalis (PSNL) Rating Maintained and Price Target Raised by M - GuruFocus
Personalis (NASDAQ:PSNL) Shares Gap Down After Insider Selling - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Q2 2025 Earnings Call Transcript - MSN
Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating - marketscreener.com
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):